Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2006;98:e50-e59
Published online before print March 23, 2006, doi: 10.1161/01.RES.0000218271.93076.c3
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
98/7/e50    most recent
01.RES.0000218271.93076.c3v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ogawa, D.
Right arrow Articles by Bruemmer, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ogawa, D.
Right arrow Articles by Bruemmer, D.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Substance via MeSH
Related Collections
Right arrow Gene regulation
Right arrow Smooth muscle proliferation and differentiation
(Circulation Research. 2006;98:e50.)
© 2006 American Heart Association, Inc.


UltraRapid Communications

Activation of Peroxisome Proliferator-Activated Receptor {gamma} Suppresses Telomerase Activity in Vascular Smooth Muscle Cells

Daisuke Ogawa, Takashi Nomiyama, Takafumi Nakamachi, Elizabeth B. Heywood, Jeffrey F. Stone, Joel P. Berger, Ronald E. Law, Dennis Bruemmer

From the Division of Endocrinology and Molecular Medicine (D.O., T. Nomiyama, T. Nakamachi, E.B.H., J.F.S., D.B.), University of Kentucky College of Medicine, Lexington; Department of Metabolic Disorders (J.P.B.), Merck Research Laboratories, Rahway, NJ; Takeda Pharmaceuticals North America (R.E.L.), Lincolnshire, Ill.

Correspondence to Dennis Bruemmer, MD, University of Kentucky College of Medicine, Department of Internal Medicine, Division of Endocrinology and Molecular Medicine, Wethington Health Sciences Building, Room 575, 900 S Limestone St, Lexington, KY 40536-0200. E-mail Dennis.Bruemmer{at}uky.edu

Activation of the peroxisome proliferator-activated receptor (PPAR) {gamma}, the molecular target for insulin sensitizing thiazolidinediones used in patients with type 2 diabetes, inhibits vascular smooth muscle cell (VSMC) proliferation and prevents atherosclerosis and neointima formation. Emerging evidence indicates that telomerase controls key cellular functions including replicative lifespan, differentiation, and cell proliferation. In the present study, we demonstrate that ligand-induced and constitutive PPAR{gamma} activation inhibits telomerase activity in VSMCs. Telomerase reverse transcriptase (TERT) confers the catalytic activity of telomerase, and PPAR{gamma} ligands inhibit TERT expression through a receptor-dependent suppression of the TERT promoter. 5'-deletion analysis, site-directed mutagenesis, and transactivation studies using overexpression of Ets-1 revealed that suppression of TERT transcription by PPAR{gamma} is mediated through negative cross-talk with Ets-1–dependent transactivation of the TERT promoter. Chromatin immunoprecipitation assays further demonstrated that PPAR{gamma} ligands inhibit Ets-1 binding to the TERT promoter, which is mediated at least in part through an inhibition of Ets-1 expression by PPAR{gamma} ligands. In VSMCs overexpressing TERT, the efficacy of PPAR{gamma} ligands to inhibit cell proliferation is lost, indicating that TERT constitutes an important molecular target for the antiproliferative effects of PPAR{gamma} ligands. Finally, we demonstrate that telomerase activation during the proliferative response after vascular injury is effectively inhibited by PPAR{gamma} ligands. These findings provide a previously unrecognized mechanism for the antiproliferative effects of PPAR{gamma} ligands and support the concept that PPAR{gamma} ligands may constitute a novel therapeutic approach for the treatment of proliferative cardiovascular diseases.


Key Words: telomerase • peroxisome proliferator-activated receptor • vascular smooth muscle cell • proliferation




This article has been cited by other articles:


Home page
Circ. Res.Home page
S. Z. Duan, M. G. Usher, and R. M. Mortensen
Peroxisome Proliferator-Activated Receptor-{gamma}-Mediated Effects in the Vasculature
Circ. Res., February 15, 2008; 102(3): 283 - 294.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
T. Minamino and I. Komuro
Vascular Cell Senescence: Contribution to Atherosclerosis
Circ. Res., January 5, 2007; 100(1): 15 - 26.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
P. Oettgen
Regulation of Vascular Inflammation and Remodeling by ETS Factors
Circ. Res., November 24, 2006; 99(11): 1159 - 1166.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
J. J. Fuster and V. Andres
Telomere Biology and Cardiovascular Disease
Circ. Res., November 24, 2006; 99(11): 1167 - 1180.
[Abstract] [Full Text] [PDF]